Dompe Receives Orphan Drug Status For Neurotrophic Keratitis Treatment | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Thursday, July 24, 2014

Email

Comments

Ocular Surgery News

The U.S. Food and Drug Administration has granted orphan drug designation for a recombinant human nerve growth factor-based treatment.

A 40 y.o. female pictured below comes to the office with swelling of both upper lids, mild shortness of breath and symptoms of dry eyes. One would expect to see as part of her work up:
1. A monocytic B cell infiltrate of her lacrimal glands
2. Pain on palpation of her lacrimal glands.
3. An elevated ACE.
4. A history of breast cancer.
Check The Answer

VISUPLAN 500 Non-Contact Tonometer
The measurement of intraocular pressure ... view product
Selecta Trio™ YAG Laser, SLT and Photocoagulation
The Lumenis Selecta® Trio™ ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us